COMP <GO>
AQST vs OCS // FREE CASH FLOW YIELD
Aquestive Therapeutics Inc. (NASDAQ) VS. Oculis Holding AG (NASDAQ) • 15-METRIC TALLY: AQST 0
— OCS 2
■ METRIC PARITY
LAST: $3.89 (-3.71%) • MKT CAP: $507.1M
fcf-yield
-10.45%
LAST: $8.26 (+0.24%) • MKT CAP: $507.5M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AQST VS. OCS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AQST | OCS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -10.45% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -22.60% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.7 | 45.3 | -2.60 | OCS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $507.1M | $507.5M | -$418.7K | OCS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AQST REV | OCS REV | AQST GROSS % | OCS GROSS % | AQST FCF | OCS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.5M | — | 58.3% | — | -$53.0M | — |
| FY 2024 | $57.6M | — | 69.0% | — | -$35.9M | — |
| FY 2023 | $50.6M | — | — | — | -$6.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AQST // BETA —
OCS // BETA —